Enzon in collaboration with NCI initiates EZN-2968 and EZN-2208 Phase I studies for a
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).